News Jounce elopes with Concentra, leaving Redx at the altar A $425 million proposed marriage between Redx Pharma of the UK and Jounce Ther
News Concentra gatecrashes Jounce and Redx’ merger party Biotech interloper is led by Kevin Tang of Tang Capital management, which owns 10% of Jounce.
News Redx slumps after it abandons trial of lead cancer drug Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.
R&D The Alderley Park Discovery Podcast: The journey to accessin... Episode 3 of the Alderley Park Discovery Podcast covers how to successfully access life science funding and investment, highlighting a range of ways companies can attract investors.
News Concerns rise over ACIP's new membership RFK Jr names eight members of the CDC's vaccine panel, some known for contrarian views on immunisation, after ousting all 17 of their predecessors.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
